Opko Health, Inc. (OPK) Position Maintained by Shikiar Asset Management Inc.
Shikiar Asset Management Inc. held its stake in shares of Opko Health, Inc. (NASDAQ:OPK) during the second quarter, Holdings Channel reports. The firm owned 38,500 shares of the biotechnology company’s stock at the end of the second quarter. Shikiar Asset Management Inc.’s holdings in Opko Health were worth $253,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Opko Health during the fourth quarter valued at $105,000. Timber Hill LLC acquired a new stake in shares of Opko Health during the first quarter valued at $114,000. World Asset Management Inc raised its stake in shares of Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,900 shares during the period. IFC Holdings Incorporated FL raised its stake in shares of Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 2,100 shares during the period. Finally, Financial Architects Inc raised its stake in shares of Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 4,800 shares during the period. Institutional investors and hedge funds own 22.94% of the company’s stock.
Opko Health, Inc. (NASDAQ OPK) opened at 6.09 on Wednesday. The company’s 50-day moving average is $6.33 and its 200 day moving average is $7.22. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15. The company’s market capitalization is $3.41 billion.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The business’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 earnings per share. Analysts predict that Opko Health, Inc. will post ($0.19) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Opko Health, Inc. (OPK) Position Maintained by Shikiar Asset Management Inc.” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/opko-health-inc-opk-position-maintained-by-shikiar-asset-management-inc/1495398.html.
Several analysts have recently weighed in on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $6.50 target price (down from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a report on Saturday. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Barrington Research lifted their price target on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $19.50 price target on shares of Opko Health in a report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. Opko Health presently has an average rating of “Hold” and a consensus target price of $14.61.
In related news, Director John A. Paganelli purchased 5,000 shares of Opko Health stock in a transaction dated Thursday, June 1st. The shares were bought at an average cost of $6.17 per share, for a total transaction of $30,850.00. Following the purchase, the director now owns 350,340 shares in the company, valued at approximately $2,161,597.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock in a transaction dated Monday, August 14th. The stock was bought at an average price of $6.15 per share, for a total transaction of $61,500.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,874,048.65. The disclosure for this purchase can be found here. Insiders have acquired 1,552,400 shares of company stock worth $9,871,527 over the last quarter. Corporate insiders own 40.19% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.